Top Markets
Coin of the day
Eiger BioPharmaceuticals, Inc. Eiger BioPharmaceuticals, Inc.

Eiger BioPharmaceuticals, Inc.

EIGR
Rang în acțiuni #36561
Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company... Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and bringing to market targeted therapies for rare and ultra-rare diseases across the United States and internationally. Its primary investigational drug, Lonafarnib, an orally administered small molecule, is currently undergoing Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection. Other promising candidates in its portfolio include Lambda, which has completed Phase II clinical trials and is designed to target type III interferon receptors; Lonafarnib, also being evaluated for progeria and progeroid laminopathies; and Avexitide, an agent for congenital hyperinsulinism that has also successfully concluded Phase II studies for post-bariatric hypoglycemia. Established in 2008, Eiger BioPharmaceuticals, Inc. maintains its headquarters in Palo Alto, California.
Preț acțiune
$1.73
Ultima sincronizare: 2025-06-17
Capitalizare de piață
$2.55M
Schimbare (1 zi)
-0.29%
Schimbare (1 an)
0.00%
Țară
US
Tranzacționează Eiger BioPharmaceuticals, Inc. (EIGR)

Categorie

Raport P/S pentru Eiger BioPharmaceuticals, Inc. (EIGR)
Raport P/S la data de 2026 TTM: 0
Conform celor mai recente rapoarte financiare și prețului acțiunilor Eiger BioPharmaceuticals, Inc., raportul P/S actual (TTM) este 0. La sfârșitul anului 2026, compania avea un P/S de 0.
Istoricul raportului P/S pentru Eiger BioPharmaceuticals, Inc. din 2026 până în 2026
Raport P/S la sfârșitul fiecărui an
An Raport P/S Schimbă
Nu sunt suficiente date pentru perioada selectată.
Raport P/S pentru companii similare sau competitoare
Companie Raport P/S Diferență raport P/S Țara
10.17 -
US
10.13 -
NL
- -
CH
- -
KR
4.74 -
BE